<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171676</url>
  </required_header>
  <id_info>
    <org_study_id>1200.20</org_study_id>
    <nct_id>NCT02171676</nct_id>
  </id_info>
  <brief_title>BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and
      efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>up to 168 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE version 3.0)</measure>
    <time_frame>up to 35 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) for different time points</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC0-∞ that is obtained by extrapolation (%AUC0-tz)</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose plasma concentration (Cpre)</measure>
    <time_frame>pre-dose on day 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 24 h following the first (C24,1) dose</measure>
    <time_frame>24 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax)</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax)</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma (λz )</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after oral administration (MRTpo)</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (V) for different time points</measure>
    <time_frame>up to 48 hours after the first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of biomarkers (EGFR (Epidermal growth factor receptor), p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki 67, p27Kip1) in skin biopsies</measure>
    <time_frame>Baseline and day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of biomarkers (EGFR, p-EGFR, HER2 (Human epidermal growth factor receptor), p-MAPK, p-Akt, Ki 67, p27Kip1) in tumour biopsies in 6 or more patients treated at the MTD</measure>
    <time_frame>Baseline and day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>up to 35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of EGFR, HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumor biopsies, or excisions obtained prior to this trial, with objective tumor responses</measure>
    <time_frame>up to 35 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Docetaxel + BIBW 2992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel + BIBW 2992</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <arm_group_label>Docetaxel + BIBW 2992</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with confirmed diagnosis of advanced, non resectable and / or
             metastatic solid tumors, of types historically known to express EGFR and/or HER2, who
             have failed conventional treatment, or for whom no therapy of proven efficacy exists,
             or who are not amenable to established forms of treatment preferably patients with
             breast, prostate, or ovarian cancer. In addition, patients with a disease amenable for
             standard treatment with docetaxel

          -  Age 18 years or older

          -  Life expectancy of at least three (3) months

          -  Written informed consent that is consistent with International Conference on
             Harmonization - Good Clinical Practice guidelines

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1

          -  Patients recovered (Common Terminology Criteria (CTC) Grade 0 or 1) from any
             therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies

          -  Patients recovered from previous surgery

        The 12 additional patients recruited at the MTD must also meet the following criteria:

          -  Measurable tumor deposits (Response Evaluation Criteria in Solid Tumors) by one or
             more techniques (X-ray, CT, MRI) and/or recognized tumor markers such as prostate
             specific antigen (prostate cancer) or cancer antigen 125 (Ovarian cancer)

        Exclusion Criteria:

          -  Active infectious disease

          -  Gastrointestinal disorders that might interfere with the absorption of the study drug
             or chronic diarrhea

          -  Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          -  Patients with untreated or symptomatic brain metastases. Patients with treated,
             asymptomatic brain metastases are eligible if there has been no change in brain
             disease status for at least eight weeks, no history of cerebral edema or bleeding in
             the past eight weeks and no requirement for steroids or anti-epileptic therapy

          -  Cardiac left ventricular function with resting ejection fraction CTC ≥ Grade 1

          -  Absolute neutrophil count (ANC) less than 1500 / mm3

          -  Platelet count less than 100 000 / mm3

          -  Bilirubin &gt; upper limit of normal (ULN)

          -  Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) &gt; 1.5 x ULN

          -  Alkaline Phosphatase &gt; 2.5 x ULN

          -  Serum creatinine &gt; 1.5 mg / dl (&gt; 132 μmol / L, SI (Système Internationale) unit
             equivalent)

          -  Women and men sexually active and unwilling to use a medically acceptable method of
             contraception

          -  Pregnancy or breast-feeding

          -  Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy
             or hormone therapy (excluding luteinising hormone-releasing hormone agonists, other
             hormones taken for breast cancer, or bisphosphonates) or participation in another
             clinical study within the past four weeks before start of therapy or concomitantly
             with this study

          -  Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before
             start of therapy or concomitantly with this study (8 weeks for trastuzumab)

          -  Patients unable to comply with the protocol

          -  Active alcohol or drug abuse

          -  Hypersensitivity to docetaxel or any component or other drug formulated with
             polysorbate 80

        The patient may be eligible for re-treatment after the previous course is finished. The
        patient will not be eligible if any of the following conditions are met:

          -  If patients latest X-ray, CT or MRI reveals progressive disease, or if clinical
             assessment reveals signs of disease progression

          -  Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course

          -  Patients fulfilling any of the Exclusion Criteria listed before as determined on day
             18 of the treatment course 1 (visit 7) or day 18 (visit R5) of the previous course

          -  Patients not recovered from any dose-limiting toxicity (DLT) 14 days after onset.
             Recovery is defined as a return to baseline level or CTC Grade &lt;= 1, whichever is
             higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

